Clinical Trial Update: Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Vactosertib and Pembrolizumab in acral and mucosal melanoma patients who progressed on prior immune checkpoint inh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Melanoma
• Mucosal Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Vactosertib (Vactosertib)

Snippet

Sponsor: Yonsei University | Conditions: Acral Melanoma, Mucosal Melanoma | Phase 2 | Status: TERMINATED